Rocket Pharmaceuticals Company Insiders

RCKT Stock  USD 14.39  0.19  1.34%   
Rocket Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Rocket Pharmaceuticals suggests that vertually all insiders are panicking. Rocket Pharmaceuticals employs about 268 people. The company is managed by 17 executives with a total tenure of roughly 6 years, averaging almost 0.0 years of service per executive, having 15.76 employees per reported executive.

Rocket Pharmaceuticals' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-21Gaurav ShahDisposed 11091 @ 13.05View
2024-07-22John MilitelloDisposed 812 @ 23.02View
2024-07-08Mark Andrew WhiteDisposed 3026 @ 20.39View
2024-05-16Martin WilsonDisposed 1048 @ 23.35View
2024-04-22John MilitelloDisposed 833 @ 22.87View
2024-04-15David P SouthwellDisposed 10000 @ 24.05View
2024-04-12David P SouthwellDisposed 70000 @ 24.36View
2024-04-08Mark Andrew WhiteDisposed 12532 @ 24.64View
2024-03-21John MilitelloDisposed 2490 @ 28.1View
2024-02-29Martin WilsonDisposed 4100 @ 29.33View
2024-02-16Martin WilsonDisposed 3576 @ 29.84View
2024-01-22John MilitelloDisposed 638 @ 27.2View
Monitoring Rocket Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.

Rocket Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Rocket Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Rocket will maintain a workforce of slightly above 270 employees by January 2025.
 
Yuan Drop
 
Covid

Rocket Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.3448) % which means that it has lost $0.3448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5927) %, meaning that it created substantial loss on money invested by shareholders. Rocket Pharmaceuticals' management efficiency ratios could be used to measure how well Rocket Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2024. Return On Capital Employed is likely to drop to -0.53 in 2024. At this time, Rocket Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 29.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 292.8 M in 2024.
Common Stock Shares Outstanding is likely to gain to about 88.2 M in 2024, despite the fact that Net Loss is likely to grow to (189.7 M).

Rocket Pharmaceuticals Workforce Comparison

Rocket Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,078. Rocket Pharmaceuticals holds roughly 268 in number of employees claiming about 5% of equities under Health Care industry.

Rocket Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rocket Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rocket Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Rocket Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
0.8333
5
6
 51,647 
 19,568 
2024-06-01
1.2222
22
18
 474,828 
 411,397 
2024-03-01
0.6364
14
22
 580,858 
 607,071 
2023-12-01
0.75
6
8
 42,115 
 46,155 
2023-09-01
0.5
7
14
 4,141,234 
 1,036,428 
2023-06-01
2.7143
19
7
 381,700 
 20,732 
2023-03-01
3.875
31
8
 2,305,049 
 222,548 
2022-06-01
9.5
19
2
 547,038 
 45,000 
2022-03-01
2.5
15
6
 896,465 
 135,562 
2021-09-01
2.0
2
1
 852,516 
 621,500 
2021-06-01
1.8333
11
6
 94,319 
 782,351 
2021-03-01
0.6667
10
15
 877,371 
 1,788,929 
2020-12-01
1.0
5
5
 347,720 
 106,761 
2020-09-01
2.0
2
1
 68,000 
 30,000 
2020-03-01
2.0
12
6
 1,062,231 
 707,904 
2019-03-01
2.75
11
4
 785,866 
 134,900 
2018-12-01
1.5
6
4
 1,338,280 
 162,125 
2018-09-01
1.0
2
2
 2.00 
 56,506 
2018-03-01
1.1
11
10
 890,300 
 1,095,634 
2017-03-01
1.6667
5
3
 755,000 
 3,266,066 
2015-12-01
0.5
1
2
 24,000 
 242,794 
2015-09-01
2.0
2
1
 33,857 
 9,857 
2015-03-01
0.5526
21
38
 16,075,976 
 40,455,800 

Rocket Pharmaceuticals Notable Stakeholders

A Rocket Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rocket Pharmaceuticals often face trade-offs trying to please all of them. Rocket Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rocket Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
PharmD MBAPresident COOProfile
John CPASenior VPProfile
CPA CPAVP, OfficerProfile
Mayo PujolsChief OfficerProfile
Martin JDChief CounselProfile
Carlos MartinChief OfficerProfile
Jonathan SchwartzChief Medical OfficerProfile
Aaron OndreyChief OfficerProfile
Isabel JDSenior OfficerProfile
Raj MBASenior OfficerProfile
Gaurav MDCEO DirectorProfile
M MBABus LeadProfile
Jessie MBAVP FinProfile
Kevin GiordanoDirector CommunicationsProfile
MBA MBAPres COOProfile
Jonathan MDChief DevelopmentProfile
MD JDSenior OfficerProfile

About Rocket Pharmaceuticals Management Performance

The success or failure of an entity such as Rocket Pharmaceuticals often depends on how effective the management is. Rocket Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rocket management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rocket management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.49)(0.51)
Return On Capital Employed(0.50)(0.53)
Return On Assets(0.43)(0.46)
Return On Equity(0.50)(0.52)
Please note, the imprecision that can be found in Rocket Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Rocket Pharmaceuticals. Check Rocket Pharmaceuticals' Beneish M Score to see the likelihood of Rocket Pharmaceuticals' management manipulating its earnings.

Rocket Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Rocket Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rocket Pharmaceuticals within its industry.

Rocket Pharmaceuticals Manpower Efficiency

Return on Rocket Pharmaceuticals Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee916.4K
Net Loss Per Executive14.4M
Working Capital Per Employee1.2M
Working Capital Per Executive19.4M

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.